TY - JOUR
T1 - Association of age, gender, and weight on maintenance dose of intravenous unfractionated heparin
AU - Verma, Siddharth
AU - Kato, Shumei
AU - Blum, Ronald
AU - Shapira, Ilan
AU - Friedmann, Patricia
AU - Varma, Mala
PY - 2010/8
Y1 - 2010/8
N2 - Unfractionated heparin (UFH) therapy is commonly used for the management of acute coronary syndrome (ACS), atrial fibrillation (AF) or atrial flutter (A-Flutter). Weight based heparin nomogram is widely used to determine the dosage of continuous intravenous infusion. Frequent monitoring is required due to the variable responses to its anticoagulant effects. We investigated factors that may influence the dose of UFH. We performed a retrospective cohort study of all patients who received continuous UFH for ACS, AF, or A-Flutter from January 2008 to December 2008 and reached maintenance dose of UFH within 48 hr. A total of 199 patients were included in this study: 42.7% were females and mean age was 66.6 ± 2.0 years. Univariate analysis revealed that age, gender, weight, serum albumin, and serum protein level were significantly associated with maintenance of UFH dose. After adjustment with multivariate analysis, age (R = -0.27, P ≤ 0.001), gender (R = -0.14, P ≤ 0.044), and weight (R = 0.54, P ≤ 0.001) remained to have significant association with maintenance UFH dose. In conclusion, we have identified not only weight but also age and gender as significant factors that may affect the maintenance of heparin dose in clinical setting.
AB - Unfractionated heparin (UFH) therapy is commonly used for the management of acute coronary syndrome (ACS), atrial fibrillation (AF) or atrial flutter (A-Flutter). Weight based heparin nomogram is widely used to determine the dosage of continuous intravenous infusion. Frequent monitoring is required due to the variable responses to its anticoagulant effects. We investigated factors that may influence the dose of UFH. We performed a retrospective cohort study of all patients who received continuous UFH for ACS, AF, or A-Flutter from January 2008 to December 2008 and reached maintenance dose of UFH within 48 hr. A total of 199 patients were included in this study: 42.7% were females and mean age was 66.6 ± 2.0 years. Univariate analysis revealed that age, gender, weight, serum albumin, and serum protein level were significantly associated with maintenance of UFH dose. After adjustment with multivariate analysis, age (R = -0.27, P ≤ 0.001), gender (R = -0.14, P ≤ 0.044), and weight (R = 0.54, P ≤ 0.001) remained to have significant association with maintenance UFH dose. In conclusion, we have identified not only weight but also age and gender as significant factors that may affect the maintenance of heparin dose in clinical setting.
UR - http://www.scopus.com/inward/record.url?scp=77955501093&partnerID=8YFLogxK
U2 - 10.1002/ajh.21751
DO - 10.1002/ajh.21751
M3 - Article
C2 - 20552595
AN - SCOPUS:77955501093
SN - 0361-8609
VL - 85
SP - 624
EP - 626
JO - American Journal of Hematology
JF - American Journal of Hematology
IS - 8
ER -